In recent trading session, ProQR Therapeutics N.V (NASDAQ:PRQR) saw 0.45 million shares changing hands at last check today with its beta currently measuring 0.36. Company’s recent per share price level of $2.46 trading at $0.3 or 14.12% at last check today assigns it a market valuation of $259.35M. That most recent trading price of PRQR’s stock is at a discount of -87.8% from its 52-week high price of $4.62 and is indicating a premium of 56.5% from its 52-week low price of $1.07. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.39 million shares which gives us an average trading volume of 499.19K if we extend that period to 3-months.
For ProQR Therapeutics N.V (PRQR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
ProQR Therapeutics N.V (NASDAQ:PRQR) trade information
Upright in the green today for gaining 14.12%, in the last five days PRQR remained trading in the green while hitting it’s week-highest on Friday, 06/27/25 when the stock touched $2.46 price level, adding 1.6% to its value on the day. ProQR Therapeutics N.V’s shares saw a change of 48.49% in year-to-date performance and have moved 27.72% in past 5-day. ProQR Therapeutics N.V (NASDAQ:PRQR) showed a performance of 45.00% in past 30-days. Number of shares sold short was 0.64 million shares which calculate 2.05 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3.75 to the stock, which implies a rise of 34.4% to its recent value today. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would jump 18.7% in reaching the projected high whereas dropping to the targeted low would mean a gain of 18.7% for stock’s current value.
ProQR Therapeutics N.V (PRQR) estimates and forecasts
This year revenue growth is estimated to fall -7.03% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 5.01M for the same. And 7 analysts are in estimates of company making revenue of 4.91M in the next quarter. Company posted 7.05M and 4.15M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 25.70% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -15.32% while estimates for its earnings growth in next 5 years are of -13.57%.
ProQR Therapeutics N.V (NASDAQ:PRQR)’s Major holders
Insiders are in possession of 18.06% of company’s total shares while institution are holding 50.95 percent of that, with stock having share float percentage of 62.18%. Investors also watch the number of corporate investors in a company very closely, which is 50.95% institutions for ProQR Therapeutics N.V that are currently holding shares of the company. PRIVIUM FUND MANAGEMENT B.V. is the top institutional holder at PRQR for having 5.58 million shares of worth $9.21 million. And as of 2024-06-30, it was holding 6.8336 of the company’s outstanding shares.
The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 3.63 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.4394 of outstanding shares, having a total worth of $6.02 million.
On the other hand, abrdn World Healthcare Fund and Delaware Group Equity Funds IV-Macquarie Healthcare Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 1.85 shares of worth $4.46 million or 1.76% of the total outstanding shares. The later fund manager was in possession of 620.0 shares on Mar 31, 2025 , making its stake of worth around $1.49 million in the company or a holder of 0.59% of company’s stock.
